| Title |
Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2012
|
| DOI | 10.1002/14651858.cd008951.pub2 |
| Pubmed ID | |
| Authors |
Helga Radner, Sofia Ramiro, Rachelle Buchbinder, Robert BM Landewé, Désirée van der Heijde, Daniel Aletaha |
| Abstract |
Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional treatment for pain might be required. Because comorbidity is highly prevalent in people with inflammatory arthritis, it is important to consider comorbidities such as gastrointestinal or liver diseases in deciding upon optimal pharmacologic pain therapy. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 33% |
| Côte d'Ivoire | 1 | 17% |
| Netherlands | 1 | 17% |
| Canada | 1 | 17% |
| Unknown | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 360 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | <1% |
| Colombia | 1 | <1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Sri Lanka | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 353 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 53 | 15% |
| Researcher | 39 | 11% |
| Student > Ph. D. Student | 37 | 10% |
| Student > Bachelor | 32 | 9% |
| Other | 21 | 6% |
| Other | 69 | 19% |
| Unknown | 109 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 129 | 36% |
| Nursing and Health Professions | 28 | 8% |
| Psychology | 13 | 4% |
| Social Sciences | 11 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 3% |
| Other | 42 | 12% |
| Unknown | 127 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#3,097,390
of 22,661,413 outputs
Outputs from Cochrane database of systematic reviews
#5,779
of 12,296 outputs
Outputs of similar age
#26,439
of 245,904 outputs
Outputs of similar age from Cochrane database of systematic reviews
#82
of 234 outputs
Altmetric has tracked 22,661,413 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,296 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 234 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.